Published in J Pharm Sci on December 08, 2016
A new initiative on precision medicine. N Engl J Med (2015) 16.03
A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet (2009) 4.32
Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology (2008) 3.28
Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood (2008) 2.18
Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem (2011) 2.11
Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet (1999) 1.79
Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut (2002) 1.74
The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther (2008) 1.70
Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther (2003) 1.67
Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther (2003) 1.65
Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clin Cancer Res (2006) 1.64
MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos (2009) 1.55
In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos (2000) 1.53
Variability of CYP3A7 expression in human fetal liver. J Pharmacol Exp Ther (2005) 1.35
Genomics of ADME gene expression: mapping expression quantitative trait loci relevant for absorption, distribution, metabolism and excretion of drugs in human liver. Pharmacogenomics J (2011) 1.31
Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist (2006) 1.30
Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab Dispos (2001) 1.29
Decreased first-pass metabolism of labetalol in chronic liver disease. Br Med J (1978) 1.21
Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex. Drug Metab Dispos (2013) 1.18
Method of the Year 2012. Nat Methods (2013) 1.17
Interindividual variability in the hepatic expression of the human breast cancer resistance protein (BCRP/ABCG2): effect of age, sex, and genotype. J Pharm Sci (2013) 1.12
Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children. Int J Pharm (2012) 1.11
The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol (1990) 1.11
Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells. Biochem Pharmacol (2011) 1.10
Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period. Eur J Biochem (1996) 1.09
Epigenomics and interindividual differences in drug response. Clin Pharmacol Ther (2012) 1.07
Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes. Pharmacogenomics (2007) 1.07
Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver. Drug Metab Dispos (2009) 1.06
Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians. Pharmacogenomics (2007) 1.05
Glycoprotein biomarker panel for pancreatic cancer discovered by quantitative proteomics analysis. J Proteome Res (2014) 1.04
Role of microRNAs in the regulation of drug metabolism and disposition. Expert Opin Drug Metab Toxicol (2009) 1.04
Optimized approaches for quantification of drug transporters in tissues and cells by MRM proteomics. AAPS J (2014) 1.03
Quantitative proteomics for epigenetics. Chembiochem (2010) 1.02
A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction. CPT Pharmacometrics Syst Pharmacol (2012) 1.02
Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6. Clin Pharmacol Ther (1998) 1.01
Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in children. CPT Pharmacometrics Syst Pharmacol (2013) 1.01
Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis. Gastroenterology (1979) 1.00
Identification of genetic variants influencing the human plasma proteome. Proc Natl Acad Sci U S A (2013) 1.00
Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport. Kidney Int (2013) 0.98
MicroRNAs and pharmacogenomics. Pharmacogenomics (2010) 0.98
Toxicological implications of modulation of gene expression by microRNAs. Toxicol Sci (2011) 0.97
Ontogeny of human hepatic and intestinal transporter gene expression during childhood: age matters. Drug Metab Dispos (2014) 0.96
Small interfering RNA in drug metabolism and transport. Curr Drug Metab (2007) 0.96
Interindividual variability in hepatic expression of the multidrug resistance-associated protein 2 (MRP2/ABCC2): quantification by liquid chromatography/tandem mass spectrometry. Drug Metab Dispos (2012) 0.95
Age related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug-drug interactions. J Clin Pharmacol (2013) 0.95
Aryl hydrocarbon receptor ligands of widely different toxic equivalency factors induce similar histone marks in target gene chromatin. Toxicol Sci (2011) 0.94
Cytochrome P450-dependent catabolism of vitamin K: ω-hydroxylation catalyzed by human CYP4F2 and CYP4F11. Biochemistry (2013) 0.94
Epigenetics: the science of change. Environ Health Perspect (2006) 0.93
MicroRNA expression is differentially altered by xenobiotic drugs in different human cell lines. Biopharm Drug Dispos (2011) 0.93
Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. J Clin Pharmacol (1989) 0.93
Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents. Clin Pharmacol Ther (2014) 0.92
Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice. J Pharmacol Exp Ther (2011) 0.91
Molecular targets of gemcitabine action: rationale for development of novel drugs and drug combinations. Curr Pharm Des (2012) 0.91
Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects. J Pharm Sci (2011) 0.90
Technetium-99m-tetrofosmin as a substrate for P-glycoprotein: in vitro studies in multidrug-resistant breast tumor cells. J Nucl Med (1996) 0.90
A study protocol for quantitative targeted absolute proteomics (QTAP) by LC-MS/MS: application for inter-strain differences in protein expression levels of transporters, receptors, claudin-5, and marker proteins at the blood-brain barrier in ddY, FVB, and C57BL/6J mice. Fluids Barriers CNS (2013) 0.90
Biotransformation of caffeine in human liver microsomes from foetuses, neonates, infants and adults. Br J Clin Pharmacol (1994) 0.89
Human Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working Group. Clin Pharmacol Ther (2015) 0.88
Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer. Br J Cancer (2013) 0.88
Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker. Eur J Clin Pharmacol (1987) 0.88
Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia. Curr Med Res Opin (2008) 0.87
Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus. Br J Pharmacol (2011) 0.86
Ontogeny of Hepatic Drug Transporters as Quantified by LC-MS/MS Proteomics. Clin Pharmacol Ther (2016) 0.86
Advances in high-resolution accurate mass spectrometry application to targeted proteomics. Proteomics (2015) 0.86
Epigenetic-dependent regulation of drug transport and metabolism: an update. Pharmacogenomics (2012) 0.85
Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content. Pharmacogenomics J (2015) 0.85
Dynamic localization of hepatocellular transporters in health and disease. World J Gastroenterol (2008) 0.85
Proteomics in epigenetics: new perspectives for cancer research. Brief Funct Genomics (2013) 0.84
A simplified PBPK modeling approach for prediction of pharmacokinetics of four primarily renally excreted and CYP3A metabolized compounds during pregnancy. AAPS J (2013) 0.83
Quantitative expression of human drug transporter proteins in lung tissues: analysis of regional, gender, and interindividual differences by liquid chromatography-tandem mass spectrometry. J Pharm Sci (2013) 0.83
Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins. Xenobiotica (2011) 0.83
Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics. Br J Clin Pharmacol (2006) 0.83
MicroRNAs as regulators of drug transporters, drug-metabolizing enzymes, and tight junctions: implication for intestinal barrier function. Pharmacol Ther (2014) 0.83
Liver expression quantitative trait loci: a foundation for pharmacogenomic research. Front Genet (2012) 0.82
Epigenetic regulation of ADME-related genes: focus on drug metabolism and transport. Drug Metab Dispos (2013) 0.82
Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis. Expert Opin Drug Metab Toxicol (2014) 0.81
Inflammation-associated microRNA-130b down-regulates cytochrome P450 activities and directly targets CYP2C9. Drug Metab Dispos (2015) 0.81
The effects of microRNA on the absorption, distribution, metabolism and excretion of drugs. Br J Pharmacol (2014) 0.81
Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes. Clin Pharmacokinet (2012) 0.81
Epigenetic regulation is a crucial factor in the repression of UGT1A1 expression in the human kidney. Drug Metab Dispos (2013) 0.80
microRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessment. Biomark Med (2015) 0.80
The angiotensin 1-converting enzyme genetic polymorphism is associated with altered substrate affinity. Pharmacogenetics (1994) 0.80
Developmental Regulation of Drug-Processing Genes in Livers of Germ-Free Mice. Toxicol Sci (2015) 0.80
VKORC1 pharmacogenetics and pharmacoproteomics in patients on warfarin anticoagulant therapy: transthyretin precursor as a potential biomarker. PLoS One (2010) 0.79
Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk. Pharm Res (2014) 0.79
Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab-Mediated Cytokine Elevations on Cytochrome P450 Enzyme Activity. CPT Pharmacometrics Syst Pharmacol (2015) 0.79
Comparison of Heavy Labeled (SIL) Peptide versus SILAC Protein Internal Standards for LC-MS/MS Quantification of Hepatic Drug Transporters. Int J Proteomics (2014) 0.79
Proteomic Analysis of the Developmental Trajectory of Human Hepatic Membrane Transporter Proteins in the First Three Months of Life. Drug Metab Dispos (2016) 0.79
Quantitative transporter proteomics by liquid chromatography with tandem mass spectrometry: addressing methodologic issues of plasma membrane isolation and expression-activity relationship. Drug Metab Dispos (2014) 0.79
Quantitative Targeted Absolute Proteomics for 28 Transporters in Brush-Border and Basolateral Membrane Fractions of Rat Kidney. J Pharm Sci (2016) 0.78
Effects of varying degrees of renal impairment on the pharmacokinetics of duloxetine: analysis of a single-dose phase I study and pooled steady-state data from phase II/III trials. Clin Pharmacokinet (2010) 0.78
MicroRNA regulation of the major drug-metabolizing enzymes and related transcription factors. Drug Metab Rev (2015) 0.78
Analysis of DNA methylation landscape reveals the roles of DNA methylation in the regulation of drug metabolizing enzymes. Clin Epigenetics (2015) 0.77
Developmental changes of aldehyde oxidase activity in young Japanese children. Clin Pharmacol Ther (2007) 0.77
Pharmacokinetics of metoprolol in patients with hepatic cirrhosis. Clin Pharmacokinet (1982) 0.77
Translational value of liquid chromatography coupled with tandem mass spectrometry-based quantitative proteomics for in vitro-in vivo extrapolation of drug metabolism and transport and considerations in selecting appropriate techniques. Expert Opin Drug Metab Toxicol (2015) 0.77
Development of Physiologically Based Pharmacokinetic/Pharmacodynamic Model for Indomethacin Disposition in Pregnancy. PLoS One (2015) 0.76
Quantitative Targeted Proteomics of Pancreatic Cancer: Deoxycytidine Kinase Protein Level Correlates to Progression-Free Survival of Patients Receiving Gemcitabine Treatment. Mol Pharm (2015) 0.76
Predictors of variation in CYP2A6 mRNA, protein, and enzyme activity in a human liver bank: influence of genetic and non-genetic factors. J Pharmacol Exp Ther (2016) 0.76
Pharmacokinetics, safety, and tolerability of solifenacin in patients with renal insufficiency. J Pharmacol Sci (2007) 0.76